HIV

View All

Pharma News | COVID-19 News | Cancer News
Merck, Dewpoint’s HIV Pipeline; Pfizer, BioNTech ‘s COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer

Merck Collaborates with Dewpoint Therapeutics to Cure HIV with Condensates   Merck has forged a collaboration with Boston-based Dewpoint Therapeutics to treat HIV using Dewpoint’s proprietary platform for condensate-based drug discovery.Under the terms of the agreement, Dewpoint is eligible for receiving ...

Find More

Telemedicine
Telemedicine: Can it be the future of healthcare?

Telemedicine is one of the fastest-growing domains in the healthcare industry. Telemedicine is the practice of providing healthcare services like evaluation, diagnosis and treatment to the patients using telecommunication technology where both the healthcare provider and patient are present at different locations. ...

Find More

Curing HIV with gene therapy
In a blind race to cure HIV, can Gene therapy be a deal-breaker?

HIV infection has become a global health burden, has claimed over 32 million lives so far since the very first case of AIDS was reported in 1981. According to a report put forward by the WHO, HIV prevalence was reported to be around 37.9million by the end of 2018.  However, HIV has grown to pandemic proport...

Find More

Marijuana
Marijuana as a treatment approach

Cannabis sativa or Cannabis indica is commonly known as Medical marijuana or cannabis (cannabinoids) are prescribed by physicians to their patients, to treat diseases, conditions or to relieve pain or symptoms. As per the National Institute of Health, Marijuana or cannabis is used for the treatment of ailments for ...

Find More

HIV treatment landscape
HIV Treatment Landscape and A New Approach

The Human immunodeficiency virus (HIV) cases have grown to pandemic extents since the first case of acquired immunodeficiency syndrome (AIDS) was reported in 1981. CDC estimates that approximately 1.1 million people in the U.S. are living with HIV today. About 15 per cent of them (1 in 7) are unaware of their infec...

Find More

HIV-Drug Resistance
Frightening Surge in HIV-drug Resistance: The Biggest Challenge Ahead

In a survey conducted by WHO, globally, 37.9 million people were tested positively living with HIV in 2018. Out of which, 62% (23.3 million) of the people were receiving antiretroviral treatment by the end of 2018. WHO, in addition to all the other Health organizations are working towards achieving the WHO/UNAIDS 9...

Find More

World Pharma News
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Find More

Notizia

Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&am...

Find More

MEDICAL MARIJUANA
What can be the scope of Medical Marijuana?

What exactly is Marijuana? In a layman language, Marijuana is the dried buds and leaves of a plant Cannabis sativa favored in warm, wild tropical climates. Earning names like pot, ganja, weed, hemp, hash, etc. it contains around 104 active cannabinoids (CBD). What they do is, they mimic the signal producing che...

Find More

Notizia

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase...

Find More